Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor–Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)

Pirtobrutinib improved PFS and TTNT, and demonstrated favorable tolerability, versus IdelaR/BR in exclusively cBTKi pretreated patients with CLL/SLL.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2025-06-06
DOI
https://doi.org/10.1200/jco-25-00166
Citations
23
Primary Topic
Chronic Lymphocytic Leukemia Research
Type
article
Field-Weighted Citation Impact
37.38
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor–Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)

George Follows, Jeff P. Sharman, Ching Ching Leow, Catherine C. Coombs et al.
23 citations
Journal of Clinical Oncology
Chronic Lymphocytic Leukemia Research
37.38
article

Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor–Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)

George Follows, Jeff P. Sharman, Ching Ching Leow, Catherine C. Coombs, Denise Y. Wang, Alessandro Sanna, Norbert Grząśko, Marisa Hill, Zoltán Mátrai, Shuhua Yi, Talha Munir, Lívia Mariano, Lindsey E. Roeker, Katherine Bao, Vishalkumar Patel, Francesc Bosch, Paul M. Barr, John M. Burke, Sebastian Grosicki, Christine I. Chen, Matthias Ritgen, Vu Minh Hua, Ananya Guntur, Paolo Ghia, Ru Feng, Wojciech J. Jurczak, Bin Liu, Lugui Qiu
article en
23 citations

Abstract

Pirtobrutinib improved PFS and TTNT, and demonstrated favorable tolerability, versus IdelaR/BR in exclusively cBTKi pretreated patients with CLL/SLL.

Journal of Clinical OncologyVol. 43(22)
Medical University of Lublin (PL), Universitat Autònoma de Barcelona (ES), Memorial Sloan Kettering Cancer Center (US), Vita-Salute San Raffaele University (IT), Medical University of Silesia (PL), Eli Lilly (United States) (US), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), University of California, Irvine (US), St James's University Hospital (GB), Princess Margaret Cancer Centre (CA), University of Rochester Medical Center (US), UNSW Sydney (AU), Sarah Cannon (US), Nanfang Hospital (CN), Universitäts Hautklinik Kiel (DE), IRCCS Ospedale San Raffaele (IT), Rocky Mountain Cancer Centers (US), Institute of Hematology & Blood Diseases Hospital (CN), Willamette Valley Cancer Institute and Research Center (US), The Maria Sklodowska-Curie National Research Institute of Oncology (PL), National Center for Epidemiology (HU), University of Florence (IT), Southern Medical University (CN)
Good health and well-being
Openalex Percentile: Top 0%
Chronic Lymphocytic Leukemia Research
37.38
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.